Abstract
Until recently, metronidazole was the first-line treatment for Clostridioides difficile infection and it is still commonly used. Though resistance has been reported due to the plasmid pCD-METRO, this does not explain all cases. Here, we investigate resistance to metronidazole in a collection of clinical isolates of C. difficile. We find that nearly all isolates demonstrate a heme-dependent increase in the minimal inhibitory concentration for metronidazole, which in some cases leads to isolates being qualified as resistant (MIC > 2 mg/L). Moreover, whole genome sequence analysis reveals a single nucleotide polymorphism in the heme responsive gene hsmA, which defines a metronidazole resistant lineage of PCR ribotype 010 / multilocus sequence type 15 isolates that also includes pCD-METRO containing strains. Together our data demonstrate that heme is crucial for medium-dependent metronidazole resistance in C. difficile.
Competing Interest Statement
The COMBACTE-CDI consortium includes partners GSK, Pfizer, DaVolterra, AstraZeneca, Sanofi Pasteur and bioMerieux. The companies did not have a role in the design and execution of the experiments for this study but provided the WGS of the isolates (GSK) and allowed examination of the FASTQ files (bioMerieux).
